ArticleJournal of molecular neuroscience : MN2025
Identification of Therapeutic Targets for Premature Ovarian Failure Through Mendelian Randomization and Colocalization Analysis Using Human Plasma Proteomics.
Article in Journal of molecular neuroscience : MN, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Causal associations between plasma proteins and premature ovarian failure through multi-omics Mendelian randomization analyses.Gynecology and pelvic medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Premature ovarian failure (POF) accelerates ovarian aging, leading to menstrual irregularities, reduced fertility, and decreased estrogen levels. Current hormone replacement therapy (HRT) cannot reverse the aging effects, highlighting the need for more targeted treatments. Genome-wide association studies (GWAS) and protein quantitative trait loci (pQTL) analyses can identify genetic variants and protein level changes associated with POF. Mendelian randomization (MR) evaluates the causal relationships between genetic variants and POF. pQTL analysis was conducted using plasma proteomics data from 54,219 participants and baseline cohort data of 34,557 individuals of European ancestry from the UK Biobank. GWAS data comprising 542 POF cases and 218,970 controls were obtained from the FinnGen database. MR analysis utilized inverse variance weighted (IVW), MR Egger, weighted median, and weighted mode methods. Colocalization analysis was performed using the "coloc" R package, and pathway enrichment analysis was conducted using the "clusterProfiler" package. Additionally, reverse MR analysis, molecular docking predictions, and summary data-based Mendelian randomization (SMR) analysis were performed. Finally, based on the scRNA-seq data of POF, analyses such as cell type annotation, gene set scoring, and cell-cell communication were performed. MR analysis identified significant causal relationships between specific proteins (BSG, CCL23, CTSC, FAP, IGSF21, LCN15, LILRB2, MUC16, PTN, SPINK1, TNFRSF1B, TNFRSF8, TNXB, and YJU2) and POF. Colocalization analysis indicated that key proteins (BSG, CCL23, FAP, and TNXB) share causal variants with POF traits. SMR analysis confirmed TNXB as a risk factor for POF. Finally, using the scRNA-seq data of POF, the expression of key gene sets was used to evaluate the scoring of different cell populations. Cell-cell communication analysis identified multiple communication pathways between high-scoring cell populations and other cell groups. The expression trend of key proteins was further verified by western blot assay. These findings are preliminary and require significant validation before clinical application. Combining pQTL and GWAS data, MR and colocalization analyses identified key proteins and genetic variants associated with POF, providing deeper insights into POF mechanisms and potential therapeutic targets.
Indexed as
Identifiers
40883588What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.